Financials

  • Market Capitalization 171.2147 M
  • Employee 226
  • Founded 1993
  • CEO Dror Bashan
  • Website www.protalix.com
  • Headquarter Delaware, United States
  • FIGI BBG000JW08N5
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-22.5
주가매출액비율
2.68

Protalix BioTherapeutics Inc (DE)

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

뉴스